Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab-800CW dose-finding fluorescence imaging study in minimally invasive esophagectomy
NL-OMON50437Phase 2Withdrawn
- Sponsor
- University Medical Center Groningen
- Start
- May 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab-IRDye800CW in esophageal adenocarcinoma (EAC), sponsored by University Medical Center Groningen. Primary endpoints: Intraoperative tumor accumulation of bevacizumab-800CW and Safety. Planned start May 2020; status: withdrawn.
02
Drugs
bevacizumab-IRDye800CW
03
Conditions
esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NL-OMON50437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50437.